Headline
The latest stories from AHA Today.
The National Institute on Minority Health and Health Disparities is accepting applications through Dec. 15 for funding to expand and improve digital health interventions to identify, treat and provide services for health conditions secondary to the COVID-19 pandemic in health disparity populations…
The Food and Drug Administration authorized the first COVID-19 diagnostic test with next generation sequencing, which can generate information about the genomic sequence of the SARS-CoV-2 coronavirus.
While the COVID-19 pandemic placed a pause on routine medical visits and non-emergency procedures, people are still giving birth and in need of support from hospitals and health systems.
The Food and Drug Administration approved a new injection to assist in tracheal intubation and provide muscle relaxation during surgeries or mechanical ventilation.
About 60% of participants in a study of young adults infected with COVID-19 on a U.S. aircraft carrier had reactive antibodies to the virus, 59% of whom also had neutralizing antibodies at the time of specimen collection, according to a report released by the Centers for Disease Control and…
AHA President and CEO Rick Pollack wrote in a blog that hospitals and health systems face a triple-hit from COVID-19: skyrocketing costs of preparing for a patient surge; a forced shutdown of regular operations for non-emergent procedures; and treating a growing number of uninsured patients.
Hospitals and other organizations have responded to COVID-19 by leveraging technology to expand outreach to patients and communities.
The National Institute on Minority Health and Health Disparities opened applications for supplemental funding to evaluate interventions to reduce COVID-19’s impact on populations that experience health disparities or other populations vulnerable to COVID-19 infection, hospitalization, or mortality…
The National Institute on Minority Health and Health Disparities opened applications for supplemental funding to evaluate interventions to reduce COVID-19’s impact on populations that experience health disparities or other populations vulnerable to COVID-19 infection, hospitalization, or mortality…
Johnson & Johnson announced it accelerated the initiation of its first human trials of its coronavirus vaccine candidate, with the trial slated to begin in the second half of July.